Biopharmaceutical major AstraZeneca has expanded its GCC in Bengaluru with a new facility, backed by an investment of ₹166 crore. The expanded hub will accommodate nearly 1,300 employees, including the addition of 400 new jobs.
This marks AstraZeneca’s second major investment in India within a year, following the recent scale-up of its Global Innovation and Technology Centre (GITC) in Chennai. Together, the company’s India operations under AstraZeneca India Private Limited (AZIPL) now employ close to 4,000 people.
“This Global Hub in Bangalore is a strategic investment that will play a vital role in advancing AstraZeneca’s bold ambition to deliver 20 new medicines by 2030,” said Jackie Crockford, Vice President, Global Business Services, AstraZeneca.
“This hub enhances our R&D capabilities by connecting us with India’s exceptional scientific and technological expertise,” said Magnus Nord, Vice President, Global Patient Safety BioPharma, AstraZeneca.
“The expansion will accelerate the development of innovative medicines and support delivery across our R&D pipeline, ultimately benefiting patients around the world.”
The Karnataka government welcomed the move, calling it a win for both employment and innovation. “This expansion aligns perfectly with our vision to create high-value employment opportunities while fostering innovation in critical sectors,” said Dinesh Gundu Rao, Minister for Health & Family Welfare, Government of Karnataka. “It reinforces Bengaluru’s status as a global hub for biotechnology and R&D,” he said.